Efficacy and safety of neoadjuvant short-course radiotherapy combined with consolidation chemotherapy for locally advanced rectal cancer
10.3760/cma.j.cn115355-20240419-00193
- VernacularTitle:新辅助短程放疗联合巩固化疗治疗局部进展期直肠癌的效果及安全性
- Author:
Yifei LI
1
;
Mingxiao CHEN
;
Jia LI
Author Information
1. 山西省肿瘤医院 中国医学科学院肿瘤医院山西医院 山西医科大学附属肿瘤医院放射治疗科，太原 030013
- Keywords:
Rectal neoplasms;
Radiotherapy, adjuvant;
Chemotherapy, adjuvant;
Prognosis;
Adverse reaction
- From:
Cancer Research and Clinic
2024;36(10):752-756
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the short-term and long-term efficacy and adverse reactions of neoadjuvant short-course radiotherapy combined with consolidation chemotherapy for locally advanced rectal cancer.Methods:A retrospective cohort study was conducted. One hundred and fifty patients with stage Ⅱ-Ⅲ rectal cancer who underwent total rectal mesentery resection in Shanxi Province Cancer Hospital from August 2015 to August 2018 were selected and divided into the short-course radiotherapy combined with consolidation chemotherapy group (study group) and the long-course synchronous radiotherapy and chemotherapy group (control group) according to the mode of neoadjuvant radiochemotherapy, with 71 and 79 cases in each group respectively. The two groups were compared in terms of recent efficacy and occurrence of adverse reactions. Kaplan-Meier method was used for survival analysis.Results:There were no statistically significant differences in the baseline clinicopathological characteristics of patients between the two groups (all P > 0.05). The proportion of patients with descending T stage [71.8% (51/71) vs. 55.7% (44/79)], descending clinical stage [66.2% (47/71) vs. 49.4% (39/79)] and the rate of pathological complete remission [21.1% (15/71) vs. 8.9% (7/79)] in the study group were higher than those in the control group, and the differences were statistically significant (all P < 0.05). The distant metastasis-free survival (DMFS) of the study group was better than that of the control group (3-year DMFS rate: 80.3% vs. 68.4%), and the difference was statistically significant ( χ2 = 4.19, P = 0.041); the differences between the study group and the control group in terms of disease-free survival (DFS) (3-year DFS rate: 80.3% vs. 78.5%) and overall survival (OS) (5-year OS rate: 91.5% vs. 83.4%) were not statistically significant (both P > 0.05). The differences in the incidences of nausea and vomiting, diarrhoea, bone marrow suppression and malaise between the two groups were not statistically significant (all P > 0.05). Conclusions:Neoadjuvant short-course radiotherapy combined with consolidation chemotherapy for locally advanced rectal cancer is safe and effective.
